retatrutide ly3437943 phase 2 trial obesity nejm 2023 (LY3437943): Mechanism of Action and Research Overview Another Promising Medication (Retatrutide) for

Doses as high as 2 mg (2,000 g) daily by mouth or 1 mg monthly by intramuscular (IM) injection have been used to treat pernicious anemia without significant side effects (136)

Symptoms of NAION Vision Loss Patients experiencing NAION after taking GLP-1 medications have reported: Sudden vision loss upon waking Blurred or foggy vision Dark or shadowy areas in vision Loss of color perception Increased sensitivity to light Headache or eye pain in some cases NAION is typically irreversible

Intramuscular injections involve injecting BPC-157 directly into a muscle belly

Additionally, it helps lower the chances of serious heart-related issues like heart attacks, strokes and cardiovascular death in adults who already have heart disease and are either obese or overweight

GLP-1 receptor agonists for Parkinsons disease